| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 49 | 55.5x | 17.3x | Around median | |
Growth | 61 | 9.2% | 7.1% | Around median | |
Quality | 66 | 4.1% | 4.5% | Top tier | |
Safety | 51 | 3.4x | 2.6x | Around median | |
Capital Return | 47 | 2.97% | 0.06% | Around median | |
Momentum | 97 | 31.5% | -1.6% | Top tier | |
Sentiment | 33 | 2 | 3 | Bottom tier |
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company whose revenue depends on a portfolio of marketed therapies and new launch programs, with a clear presence in gastrointestinal diseases, plasma-derived therapies, oncology, and neurological and immune diseases. In Q1 FY2026 (ending 2026-06), existing core brands accounted for 58% of revenue and grew 2.3% at constant exchange rates, led by ENTYVIO's resilience, while new launches accounted for 4% and grew 22.6%, supported by FRUZAQLA, LIVTENCITY, ADZYNMA, and QDENGA. In contrast, the mature portfolio faces loss-of-exclusivity pressure, including continued erosion from VYVANSE generics in the United States.
The company recorded revenue of 1.22 trillion yen in Q1 FY2026 (ending 2026-06), up 10.2% year over year from 1.11 trillion yen, but core revenue declined 0.5% at constant exchange rates after currency movements added 118.2 billion yen. Gross margin was 66.7% versus 65.2% in Q1 FY2025 (ending 2025-06), while operating margin was 16.5% versus 16.7%. Net income was 113.2 billion yen, and operating cash flow was 127.6 billion yen.
For the last 12 months through 2026-06-30, Takeda generated revenue of 4.89 trillion yen, net income of 192.3 billion yen, and free cash flow of 560.2 billion yen. The balance sheet in Q1 FY2026 (ending 2026-06) shows cash and investments of 461.0 billion yen versus total debt of 4.94 trillion yen, making deleveraging and disciplined launch funding an important part of monitoring the investment case. During the 90 days through 2026-09-30, 20 open-market sales by 13 insiders totaled $13.1 million, including $2.5 million under 10b5-1 plans and $10.6 million outside them, with no purchases recorded.
Q1 FY2026 (2026-06)
When: 2026-10-29
Annual revenue growth compared with the 10.2% threshold
Operating margin compared with the 16.5% threshold
When: Q2 FY2026
Number of ORZEYFUL approvals in the United States and Japan compared with the target of two approvals
The discounted cash flow model indicates $6.51 within a range of $3.68 to $11 and at a discount rate of 8.8%; it is a low-confidence indicative estimate measuring the value of the cash Takeda can generate. The industry-multiple valuation indicates $6.50 within a range of $4.52 to $13, using a median multiple of 17.6 on the last 12 months' earnings among 19 companies; it is also a low-confidence indicative estimate and measures the company as its peers are priced. The two methods agree almost completely at their midpoint estimates, but the difference between their ranges reflects the first method's reliance on cash flow forecasts and discounting and the second method's reliance on Takeda's earnings and industry-company pricing. Analyst consensus rates the stock a "Buy," while recognizing that analyst targets inherently tend toward optimism, whereas the cash flow model tends to be conservative.
Figures in the text are as of 2026-09-30; the live price is shown at the top of the page.
Takeda relies on established drug brands such as ENTYVIO and on plasma-derived therapies, alongside a launch category that includes FRUZAQLA, LIVTENCITY, ADZYNMA, and QDENGA. In Q1 FY2026 (ending 2026-06), existing core brands represented 58% of revenue and grew 2.3% at constant exchange rates. New launches represented only 4%, but grew 22.6%, showing that the current portfolio remains the primary source of revenue while the company builds its next growth wave.
Revenue reached 1.22 trillion yen in Q1 FY2026 (ending 2026-06), up 10.2% year over year, and net income reached 113.2 billion yen. Gross margin increased to 66.7% from 65.2% in the comparable quarter, but operating margin declined slightly to 16.5% from 16.7%. Core revenue also declined 0.5% at constant exchange rates, while currencies added 118.2 billion yen to reported revenue.
Automated analysis for informational purposes only — not investment advice.
Last 12 months to 2026-06-30
When: FY2026
Free cash flow compared with the target range of 650 billion yen to 750 billion yen
ORZEYFUL is an orexin agonist targeting the deficiency that causes type 1 narcolepsy, and two phase 3 studies met all fourteen primary and secondary endpoints. The drug received its first approval in China, and decisions in the United States and Japan were expected in Q2 FY2026, with launches targeted for the second half of 2026. Takeda initially targets diagnosed patients receiving existing treatments, then aims to expand the market by improving diagnosis, with the drug expected to be used as monotherapy.
rusfertide is under FDA priority review for the treatment of polycythemia vera, and Takeda targets a U.S. launch during the second half of 2026 after obtaining full global commercialization responsibility. For zasocitinib, the company targets a U.S. launch during the first half of 2027, after the PASI 100 achievement rate exceeded 35% at week 16 and it outperformed deucravacitinib. Takeda also expects phase 2 data for zasocitinib in Crohn's disease and ulcerative colitis by the end of FY2026.
In Q1 FY2026 (ending 2026-06), Takeda held cash and investments of 461.0 billion yen versus total debt of 4.94 trillion yen. In contrast, operating cash flow reached 953.6 billion yen and free cash flow reached 560.2 billion yen during the last 12 months through 2026-06-30. Management targets free cash flow of between 650 billion yen and 750 billion yen for FY2026, making achievement of this range important for funding launches and managing leverage.
During the 90 days through 2026-09-30, 13 insiders executed 20 open-market sales with a total value of $13.1 million. The sales were split between $2.5 million under prearranged 10b5-1 trading plans and $10.6 million outside those plans, and the largest seller was an executive officer with sales worth $5.3 million. No purchases were recorded during the period, with their value totaling $0.